Overview

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compare the response of the kidney for calcium and phosphate.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline